ScreenerHero

BNR Burning Rock Biotech Limited

NAS · US · Healthcare · Diagnostics & Research · brbiotech.com
15.18USD-5.77%Mkt Cap: 160.09M $P/E: —

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, an…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7
HeadlineSourceTime
Older
Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value?

Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, moves that triggered a sharp selloff in the stock. See our latest analysis for Myriad Genetics. For investors tracking Myriad Genetics over a longer horizon, the recent earnings miss and lower 2026 revenue guidance have accelerated an already weak trend. The 1-day share price return of down 46.74% adds to a year-to-date share price decline of...

Simply Wall St.
Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

In late July 2026, Myriad Genetics reported second-quarter 2026 results showing sales of US$190.7 million and a reduced net loss of US$43.2 million, while also lowering full-year 2026 revenue guidance to US$770 million–US$790 million due to weaker prenatal health test volumes and more cautious expectations for revenue per test. At the same time, Myriad’s longstanding partnership with Burning Rock Biotech advanced with a new global HRD technology licensing agreement, underscoring how...

Simply Wall St.